Document Detail


Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
MedLine Citation:
PMID:  19434652     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We evaluated whether detection of prostate-specific antigen (PSA) and human kallikrein 2 (hK2) transcripts in the peripheral blood during brachytherapy could predict biochemical outcome. METHODS: Eighty-one patients who underwent (125)Iodine-based brachytherapy for localized prostate cancer (Gleason score <8, PSA <20 ng/ml, stage <T3), participated in the study. Brachytherapy was given to 35 patients as monotherapy, to 36 in combination with androgen deprivation therapy (ADT), and to 10 in combination with external beam radiation and ADT. Blood samples from 80 patients were available for analysis. Nested RT-PCR means was used to detect mRNA expression of PSA and hK2 in the peripheral blood. Their expression was analyzed before, during and 1 month after brachytherapy. Patients' biochemical outcome (blood PSA levels) during 3 years of follow-up was correlated with the PCR results. RESULTS: The incidence of PSA and hK2 mRNA expression in the peripheral blood was significantly higher during than before or after the procedure. Patients with concurrent positive PSA and hK2 PCR results during brachytherapy had higher postoperative blood PSA values and a slower decline rate of PSA compared with patients with negative PSA and hK2 PCR results. No correlations were found between pre- and postbrachytherapy PCR results and biochemical outcome. ADT was the only significant factor that affected PSA and hK2 mRNA expression during brachytherapy. CONCLUSIONS: Our short-term results suggest that detection of PSA and hK2 transcripts in the peripheral blood of prostate cancer patients during brachytherapy could serve as a predictor of biochemical outcome.
Authors:
Nicola J Mabjeesh; Sharon Amir; Amira Stenger; Juza Chen; Haim Matzkin
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Prostate     Volume:  69     ISSN:  1097-0045     ISO Abbreviation:  Prostate     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-06-29     Completed Date:  2009-07-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1235-44     Citation Subset:  IM    
Affiliation:
Department of Urology, Tel Aviv Sourasky Medical Center, Tel Aviv University, 6 Weizmann Street, Tel Aviv 64239, Israel. nicolam@tasmc.health.gov.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Androgens / metabolism
Brachytherapy*
Follow-Up Studies
Humans
Male
Middle Aged
Postoperative Period
Predictive Value of Tests
Prognosis
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*,  diagnosis,  radiotherapy*
RNA, Messenger / blood
Tissue Kallikreins / blood*
Treatment Outcome
Tumor Markers, Biological / blood*
Chemical
Reg. No./Substance:
0/Androgens; 0/RNA, Messenger; 0/Tumor Markers, Biological; EC 3.4.21.35/Tissue Kallikreins; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Methods to improve reliability of video-recorded behavioral data.
Next Document:  Proteolysis of peptide dendrimers.